Thus, it is conceivable that classes of HDAC inhibitors, different potencies in inhibiting each member of the HDAC family, types of target cells, types of GvHD models, and dosage and time periods of inhibitors could result in these contradictory outcomes in GvHD. The gene discussed is HDAC9; the disease is graft versus host disease.